BC Week In Review | Oct 7, 2013
Clinical News

Zomarist vildagliptin/metformin regulatory update

Germany's Federal Joint Committee (G-BA) said in a final benefit assessment that Zomarist vildagliptin/metformin from Novartis to treat Type II diabetes has "no additional benefit." The assessment is in line with a July preliminary assessment...
BC Extra | Oct 2, 2013
Company News

G-BA assesses DPP-4 inhibitors

Germany's Federal Joint Committee (G-BA) issued final benefit assessments for a group of dipeptidyl peptidase-4 inhibitors ( DPP-4 ) inhibitors to treat Type II diabetes that were launched before drug pricing law AMNOG came into effect. The...
BC Week In Review | Jul 15, 2013
Clinical News

Zomarist vildagliptin/metformin regulatory update

Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) issued a preliminary benefit assessment for Zomarist vildagliptin/metformin from Novartis saying that the Type II diabetes drug has "no additional benefit" because the company did not...
BC Extra | Jul 2, 2013
Company News

IQWiG assesses DPP-4 inhibitors

Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) issued preliminary benefit assessments for a group of dipeptidyl peptidase-4 (DPP-4) inhibitors that were launched before drug pricing law AMNOG came into effect. IQWiG rejected Janumet...
BC Week In Review | May 20, 2013
Company News

Novartis endocrine/metabolic news

A German court dismissed a suit from Novartis seeking to block the assessment of the pharma's Type II diabetes drugs in the dipeptidyl peptidase-4 (DPP-4) inhibitor (gliptin) class. Preliminary assessments on the drugs - Galvus vildagliptin...
BC Extra | May 16, 2013
Company News

Novartis loses bid to stop German gliptin review

A German court on Wednesday dismissed a suit from Novartis AG (NYSE:NVS; SIX:NOVN) seeking to block the assessment of the pharma's Type II diabetes drugs in the dipeptidyl peptidase-4 (DPP-4) inhibitor (gliptin) class. Preliminary assessments...
BC Extra | Mar 8, 2013
Politics & Policy

Germany seeks to prevent AMNOG assessment suits

A draft bill from Germany's Federal Ministry of Health (BMG) that was obtained by BioCentury would clarify language in AMNOG to specify that assessments of drugs marketed prior to January 2011, when the drug pricing...
BC Week In Review | Mar 4, 2013
Company News

Novartis endocrine/metabolic news

A German court said pending litigation from Novartis is not cause for suspending the review of marketed dipeptidyl peptidase-4 (DPP-4) inhibitors by Germany's Federal Joint Committee (G-BA). The written decision from the State Social Court...
BC Extra | Mar 1, 2013
Company News

Novartis suit, gliptin review to continue in Germany

A German court on Thursday said pending litigation from Novartis AG (NYSE:NVS; SIX:NOVN) is not cause for suspending the review of marketed dipeptidyl peptidase-4 (DPP-4) inhibitors by Germany's Federal Joint Committee (G-BA). The written decision...
BC Week In Review | Feb 18, 2013
Company News

Novartis endocrine/metabolic news

Novartis filed a complaint in a German court in December through which it is seeking to block an assessment of its dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) which were launched before Germany's drug pricing law AMNOG...
Items per page:
1 - 10 of 18